Voyager Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities in USD from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Voyager Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2015 to Q1 2025.
  • Voyager Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $82K, a 99.9% decline year-over-year.
  • Voyager Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $114M, a 239% increase from 2023.
  • Voyager Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $33.6M, a 2931% increase from 2022.
  • Voyager Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.11M, a 81.4% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Voyager Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $82K -$113M -99.9% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q1 2024 $113M +$81.6M +260% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q1 2023 $31.3M +$31.3M +260783% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q1 2022 $12K -$16K -57.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q1 2021 $28K -$6K -17.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q1 2020 $34K -$77.9M -100% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q1 2019 $77.9M +$76.1M +4159% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q1 2018 $1.83M +$1.23M +204% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q1 2017 $602K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10

Voyager Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $114M +$80.4M +239% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-11
2023 $33.6M +$32.5M +2931% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-11
2022 $1.11M +$498K +81.4% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-11
2021 $612K -$2.55M -80.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $3.16M -$77.8M -96.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-07
2019 $81M +$76.2M +1605% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-08
2018 $4.75M -$55.2M -92.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $59.9M +$59.4M +11558% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
2016 $514K -$177M -99.7% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-26
2015 $178M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.